- Home
- ESS vs NTRA Comparison
ESS vs NTRA Comparison
Compare ESS & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESS
- NTRA
- Stock Information
- Founded
- ESS 1971
- NTRA 2003
- Country
- ESS United States
- NTRA United States
- Employees
- ESS N/A
- NTRA N/A
- Industry
- ESS Real Estate Investment Trusts
- NTRA Medical Specialities
- Sector
- ESS Real Estate
- NTRA Health Care
- Exchange
- ESS Nasdaq
- NTRA Nasdaq
- Market Cap
- ESS 18.7B
- NTRA 22.1B
- IPO Year
- ESS 1994
- NTRA 2015
- Fundamental
- Price
- ESS $294.71
- NTRA $162.31
- Analyst Decision
- ESS Hold
- NTRA Strong Buy
- Analyst Count
- ESS 22
- NTRA 17
- Target Price
- ESS $297.35
- NTRA $165.88
- AVG Volume (30 Days)
- ESS 466.1K
- NTRA 1.3M
- Earning Date
- ESS 02-04-2025
- NTRA 02-27-2025
- Dividend Yield
- ESS 3.49%
- NTRA N/A
- EPS Growth
- ESS 82.71
- NTRA N/A
- EPS
- ESS 11.54
- NTRA N/A
- Revenue
- ESS $1,826,249,000.00
- NTRA $1,531,955,000.00
- Revenue This Year
- ESS N/A
- NTRA $56.11
- Revenue Next Year
- ESS $3.89
- NTRA $9.76
- P/E Ratio
- ESS $25.54
- NTRA N/A
- Revenue Growth
- ESS 8.71
- NTRA 54.94
- 52 Week Low
- ESS $225.40
- NTRA $69.91
- 52 Week High
- ESS $317.73
- NTRA $183.00
- Technical
- Relative Strength Index (RSI)
- ESS 58.96
- NTRA 40.88
- Support Level
- ESS $287.37
- NTRA $168.15
- Resistance Level
- ESS $293.79
- NTRA $180.41
- Average True Range (ATR)
- ESS 6.25
- NTRA 7.08
- MACD
- ESS 0.60
- NTRA -1.24
- Stochastic Oscillator
- ESS 71.85
- NTRA 14.58
About ESS Essex Property Trust Inc.
Essex Property Trust owns a portfolio of 254 apartment communities with over 62,000 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.